RT @RichardPAConway: Devauchelle-Pensec et al. SEMAPHORE RCT- tocilizumab in refractory PMR. TCZ treated GC dependent pa

Tweet Author

Tweet Content

Devauchelle-Pensec et al. SEMAPHORE RCT- tocilizumab in refractory PMR. TCZ treated GC dependent patients - better disease activity, reduced GC, less flare, more frequent GC-free remission @RheumNow #ACR22 Abstr#1106 https://t.co/UevgjF8di5 https://t.co/GmXqasNscp

Links

Effect of Tocilizumab on Disease Activity in Patients with Active Polymyalgia R… https://acrabstracts.org/abstract/effect-of-tocilizumab-on-disease-activity-in-…

Copays Reduce Adherence to SLE Medications

RheumNowâs expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content is chosen by

Tweet Author

RheumNow

Tweet Content

RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its Faculty

RT @Janetbirdope: What to do next? Dazodalibep Rx in bDMARDs IR #RA pts. Dazo is a novel CD40 ligand antagonist Phase II

Tweet Author

Janetbirdope

Tweet Content

What to do next? Dazodalibep Rx in bDMARDs IR #RA pts. Dazo is a novel CD40 ligand antagonist Phase II RCT. N=78, multi dose phase II RCT. All doses improved DAS28. Dosing interval may be prolonged over time. Awaiting phase 3. Abst#2008 #ACR22 @RheumNow https://t.co/IrzflycKZp

RT @DrPetryna: #abst2132 #acr22 @rheumnow safety ofÂ Deucravacitinib Ph2PsA&ph3PSO trial: no Î from BL in hematolog

Tweet Author

DrPetryna

Tweet Content

#abst2132 #acr22 @rheumnow safety of Deucravacitinib Ph2PsA&ph3PSO trial: no Δ from BL in hematology, chemistry, or lipid labs. JAK 1/2/3 Effects on hem, hepatic, CPK, and cholesterol lab parameters not observed over 16 wks of DEUC at doses up to 12 mg QD & in combo w/csDMARDs. https://t.co/bjGEYp4GcJ

RT @RichardPAConway: Hoffmann-Vold et al. SSc ILD frequently progresses even in long-standing SSc. Not just a disease of

Tweet Author

RichardPAConway

Tweet Content

Hoffmann-Vold et al. SSc ILD frequently progresses even in long-standing SSc. Not just a disease of early SSc! @RheumNow #ACR22 Abstr#1536 https://t.co/nKiY2xFxfk https://t.co/W7SDm6QFpQ

Links

Progressive Interstitial Lung Disease Is Frequent Also in Late Disease Stages i… https://acrabstracts.org/abstract/progressive-interstitial-lung-disease-is-freq…

RT @RichardPAConway: Ghaffar et al. Chronic abdominal periaortitis. Imaging improved in only 57% and resolved in 9%. Inc

Tweet Author

RichardPAConway

Tweet Content

Ghaffar et al. Chronic abdominal periaortitis. Imaging improved in only 57% and resolved in 9%. Incident aneurysms rare 8%. Older age and secondary cause assoc greater likelyhood improvement, smokers 2 times less likely. @RheumNow #ACR22 Abstr#1576 https://t.co/jS9djx3ZtU https://t.co/OFW2Jk7gGW

Links

Clinical Presentation and Outcome of Patients with Chronic Abdominal Periaortit… https://acrabstracts.org/abstract/clinical-presentation-and-outcome-of-patients…

RT @ericdeinmd: 13S150. Draft ACR/EULAR APLS Classif Crit #ACR22 Entry: Clinical & +aPL w/in 3 yr Then: Additive cri

Tweet Author

ericdeinmd

Tweet Content

13S150. Draft ACR/EULAR APLS Classif Crit #ACR22 Entry: Clinical & +aPL w/in 3 yr Then: Additive crit -Don't count other cause Clinical Domains: Macrovasc VTE, Macrovasc AT, Microvasc, Obst, Cardiac, Hematology Lab: +LA, aCL/B2GP IgM/IgG/titer Total: 3+ clin, 3+ lab @RheumNow https://t.co/YeKW0orjZC

RT @DrTrishHarkins: â¬ï¸ serum anti-CCP3 Ab, absence IA ð StopRA trial - ironically stoppedð â hydroxychloro

Tweet Author

DrTrishHarkins

Tweet Content

⬆️ serum anti-CCP3 Ab, absence IA 👉 StopRA trial - ironically stopped🛑 ❌ hydroxychloroquine not superior to PBO in preventing/ delaying IA 👉rate of conversion to RA in CCP3+ve ~35% @ 3yrs #ACR22 @RheumNow Abst#1604

RT @KDAO2011: âAs long as you are practicing rheumatology, your legal risk is low.â - @greerdonley, law professor, o

Tweet Author

KDAO2011

Tweet Content

“As long as you are practicing rheumatology, your legal risk is low.” - @greerdonley, law professor, on how rheumatologists should not let fear of legal consequences interfere w/practicing high quality evidenced based medicine for our patients #ReproductiveRheum #ACR22 @rheumnow

Topics

RT @RichardPAConway: Devauchelle-Pensec et al. SEMAPHORE RCT- tocilizumab in refractory PMR. TCZ treated GC dependent pa

Copays Reduce Adherence to SLE Medications

RheumNowâs expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content is chosen by

RT @Janetbirdope: What to do next? Dazodalibep Rx in bDMARDs IR #RA pts. Dazo is a novel CD40 ligand antagonist Phase II

RT @DrPetryna: #abst2132 #acr22 @rheumnow safety ofÂ Deucravacitinib Ph2PsA&ph3PSO trial: no Î from BL in hematolog

RT @RichardPAConway: Hoffmann-Vold et al. SSc ILD frequently progresses even in long-standing SSc. Not just a disease of

RT @RichardPAConway: Ghaffar et al. Chronic abdominal periaortitis. Imaging improved in only 57% and resolved in 9%. Inc

RT @ericdeinmd: 13S150. Draft ACR/EULAR APLS Classif Crit #ACR22 Entry: Clinical & +aPL w/in 3 yr Then: Additive cri

RT @DrTrishHarkins: â¬ï¸ serum anti-CCP3 Ab, absence IA ð StopRA trial - ironically stoppedð â hydroxychloro

RT @KDAO2011: âAs long as you are practicing rheumatology, your legal risk is low.â - @greerdonley, law professor, o

Do you get our email newsletter?

RT @RichardPAConway: Devauchelle-Pensec et al. SEMAPHORE RCT- tocilizumab in refractory PMR. TCZ treated GC dependent pa

Copays Reduce Adherence to SLE Medications

RheumNowâs expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content is chosen by

RT @Janetbirdope: What to do next? Dazodalibep Rx in bDMARDs IR #RA pts. Dazo is a novel CD40 ligand antagonist Phase II

RT @DrPetryna: #abst2132 #acr22 @rheumnow safety ofÂ Deucravacitinib Ph2PsA&amp;ph3PSO trial: no Î from BL in hematolog

RT @RichardPAConway: Hoffmann-Vold et al. SSc ILD frequently progresses even in long-standing SSc. Not just a disease of

RT @RichardPAConway: Ghaffar et al. Chronic abdominal periaortitis. Imaging improved in only 57% and resolved in 9%. Inc

RT @ericdeinmd: 13S150. Draft ACR/EULAR APLS Classif Crit #ACR22 Entry: Clinical &amp; +aPL w/in 3 yr Then: Additive cri

RT @DrTrishHarkins: â¬ï¸ serum anti-CCP3 Ab, absence IA ð StopRA trial - ironically stoppedð â hydroxychloro

RT @KDAO2011: âAs long as you are practicing rheumatology, your legal risk is low.â - @greerdonley, law professor, o

RheumNowâs expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content is chosen by

RT @DrPetryna: #abst2132 #acr22 @rheumnow safety ofÂ Deucravacitinib Ph2PsA&ph3PSO trial: no Î from BL in hematolog

RT @ericdeinmd: 13S150. Draft ACR/EULAR APLS Classif Crit #ACR22 Entry: Clinical & +aPL w/in 3 yr Then: Additive cri

RT @DrTrishHarkins: â¬ï¸ serum anti-CCP3 Ab, absence IA ð StopRA trial - ironically stoppedð â hydroxychloro

RT @KDAO2011: âAs long as you are practicing rheumatology, your legal risk is low.â - @greerdonley, law professor, o